Prevention and treatment of skeletal disorder with ep2 receptor subtype selective prostaglandin e2 agonists
CA 2275595 C · Owner: Cameron, Kimberly O'Keefe · Inventors: Ke, Hua Zhu; Cameron, Kimberly O'Keefe; Thompson, David Duane
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Methods for treating (e.g. preventing bone loss) a mammal having a condition which presents with low bone mass or other skeletal disorders for promoting fracture healing comprising inhibiting the EP2 receptor subtype by administering to a mammal a therapeutically effective amount of an EP2 receptor subtype agonist.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 27, 1997 and granted August 5, 2003. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended November 27, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 27, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.